| 2023-LICE-70096 | |
| Researchers at Purdue have developed a new method to treat obesity using canary seed peptide isolates (CSP). In a mouse model, administration of CSP was found to prevent weight gain and decrease food intake (prolonged satiety) without causing the undesirable side effects found in other anti-obesity medications such as oily spotting, abdominal cramping, fecal incontinence, and fat-soluble vitamin deficiencies. The researchers tested CSP isolates on mice eating a "western diet" (rich in fat and cholesterol) and compared them to mice fed a western diet with orlistat (an anti-obesity medication), mice on a "normal (standard) diet" (as a control), and mice fed on a western diet alone. The researchers found that mice treated with the correct amount of CSP exhibited lower weight gain, decreased feed intake and hyperlipidemia, increased glucose tolerance, and reduced fat gain in the liver, comparable to the effects measured from the mice treated with orlistat, but without the side effects. This technology, which has been demonstrated in a mouse model, could be used to help treat people with obesity and help prevent further progression in the form of metabolic diseases such as hypertension, diabetes, and hepatic steatosis. Technology Validation: - Mice treated with CSP had a lower food intake than those on the normal diet (ND), western diet (WD), and those treated with orlistat. Mice treated with CSP had a similar decreased weight gain to those treated with orlistat. - Mice treated with CSP had a lower blood glucose content than those treated with orlistat and those fed a WD, but a higher glucose content than those fed ND - Mice treated with CSP had similar organ weights to those treated with orlistat, and showed decreased fat weight compared to mice on the WD. - Fecal matter was collected weekly and the moisture, crude protein, crude fat, crude fiber contents were analyzed to confirm that CSP does not cause oily spotting or fecal incontinence. Advantages: - Decreased weight gain - Induce satiety - Absent side effects compared to obesity medications Applications: - Pharmaceutical industry - Food industry - Healthcare and weight management |
|
|
|
|
Apr 6, 2023
Provisional-Patent
United States
(None)
(None)
|
|
|
Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |
